Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 13:8:16.
doi: 10.1186/s40364-020-00195-3. eCollection 2020.

Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study

Affiliations

Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study

Zhebin Du et al. Biomark Res. .

Abstract

Background: Identifying the temporal trends of kidney cancer (KC) incidence in both the past and the future at the global and national levels is critical for KC prevention.

Methods: We retrieved annual KC case data between 1990 and 2017 from the Global Burden of Disease (GBD) online database. The average annual percentage change (AAPC) was used to quantify the temporal trends of KC age-standardized incidence rates (ASRs) from 1990 to 2017. Bayesian age-period-cohort models were used to predict KC incidence through 2030.

Results: Worldwide, the number of newly diagnosed KC cases increased from 207.3 thousand in 1990 to 393.0 thousand in 2017. The KC ASR increased from 4.72 per 100,000 to 4.94 per 100,000 during the same period. Between 2018 and 2030, the number of KC cases is projected to increase further to 475.4 thousand (95% highest density interval [HDI] 423.9, 526.9). The KC ASR is predicted to decrease slightly to 4.46 per 100,000 (95% HDI 4.06, 4.86). A total of 90, 2, and 80 countries or territories are projected to experience increases, remain stable, and experience decreases in KC ASR between 2018 and 2030, respectively. In most developed countries, the KC incidence is forecasted to decrease irrespective of past trends. In most developing countries, the KC incidence is predicted to increase persistently through 2030.

Conclusions: KC incidence is predicted to decrease in the next decade, and this predicted decrease is mainly driven by the decreases in developed countries. More attention should be placed on developing countries.

Keywords: Incidence; Kidney cancer; Modeling study; Prediction; Temporal trends.

PubMed Disclaimer

Conflict of interest statement

Competing interestsNone.

Figures

Fig. 1
Fig. 1
The increasing trends in the numbers of kidney cancer cases between 1990 and 2030 at the global level by sex (a, both sexes; b, male; c, female). The error bar denotes the 95% highest density interval (HDI) of the prediction values
Fig. 2
Fig. 2
The temporal trends of age-standardized incidence rates (ASRs, per 100,000) of kidney cancer between 1990 and 2030 at the global level in both sexes (a), males (b), and females (c). The open dots represent the observational values from GBD dataset, and the brick red shadow denotes the 95% highest density interval of prediction values. The predictive mean value is shown as a black solid line. The vertical dashed line indicates where the prediction starts
Fig. 3
Fig. 3
The changing trends in the number of kidney cancer cases between 1990 and 2030 by age (a, 0–19 years; b, 20–39 years; c, 40–64 years; d, ≥65 years). The vertical dashed line indicates where the prediction starts
Fig. 4
Fig. 4
The global distribution and the average annual percentage changes (AAPCs) in age-standardized incidence rates (ASRs, per 100,000) of kidney cancer at the national level. (a ASR of kidney cancer in 2017; b ASR of kidney cancer in 2030; c AAPC of kidney cancer ASR between 1990 and 2017; d AAPC of kidney cancer ASR between 2018 and 2030)
Fig. 5
Fig. 5
The correlations between the average annual percentage changes (AAPCs) in kidney cancer incidence in 1990–2017 and that in 2018–2030 at the national level, by sociodemographic index (SDI). The ρ and P values were derived from Pearson correlation tests

References

    1. Gansler T, Fedewa S, Amin MB, Lin CC, Jemal A. Trends in reporting histological subtyping of renal cell carcinoma: association with cancer center type. Hum Pathol. 2018;74:99–108. doi: 10.1016/j.humpath.2018.01.010. - DOI - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84. doi: 10.1016/j.eururo.2018.08.036. - DOI - PMC - PubMed
    1. Scelo G, Larose TL. Epidemiology and risk factors for kidney cancer. J Clin Oncol. 2018;36(36):JCO2018791905. - PMC - PubMed
    1. Li P, Znaor A, Holcatova I, Fabianova E, Mates D, Wozniak MB, et al. Regional geographic variations in kidney cancer incidence rates in European countries. Eur Urol. 2015;67:1134–1141. doi: 10.1016/j.eururo.2014.11.001. - DOI - PubMed